Clinical research on the theraputic effect of recombined human endostatin with interventional therapy for hepatic metastatic tumor from gastrointestinal tract

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-10000944

Enrollment

Unknown

Registered

2010-07-14

Start date

2010-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic metastatic tumor

Interventions

1:treated with only interventional therapy

2:treated with rh-endostatin and interventional ther

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. history of gastroenteric tumor completed resection; 2. medical imaging identification; 3. pathological identification; 4. tumor marker increase; 5. without indicationof surgical therapy and other therapies; 6. without sever organ disfunction and nonfunction; 7. initial treatment or repeated treatment without any therapy in recent 4 weeks.

Exclusion criteria

Exclusion criteria: 1. primary tumor recurrence or advance; 2. with indication of surgical therapy or other total correction therapies; 3. with sever organ functional disorder not suitable for interventioanal therapy; 4. with any therapies in recent 4 weeks; 5. with sever infection or other diseases.

Design outcomes

Primary

Measure	Time frame
MR prfusion;plain CT;plain MR;life time;	—

Secondary

Measure	Time frame
quality of life;tumor markers;	—

Countries

China

Contacts

Public ContactJian Xu

xujan3212@sina.com+86 13851656307

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026